Tag Wisconsin Alumni Research Foundation
From educational software to embryonic stem cells, University of Wisconsin–Madison faculty, students and staff are well-known for creating new knowledge and businesses - and an ongoing count of university-related startups bears that out.
The WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility (WCBF) announced today (July 6) the release of the first current Good Manufacturing Practices (cGMP) feeder-independent pluripotent stem cell banks available for sale and distribution to researchers worldwide.
The second annual Wisconsin Science and Technology Symposium, to be held July 23 and 24, will bring together science and technology researchers, entrepreneurs, and investors from across the state to help them share ideas and spark new collaborations.
The perspectives of the inventor, investor and CEO of Madison's rising startup radiopharmaceutical company Cellectar Inc. will be the focus of the Wisconsin Alumni Research Foundation's Gilson Discovery Series event, to be held at 5 p.m. on Wednesday, June 24, at the Fluno Center, 601 University Ave.
Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin–Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.
Sustainability will be the focus of the eighth annual International Bioethics Forum to be held in Madison Thursday and Friday, April 23 and 24.
In early April, Adam Wilson posted a status update on the social networking Web site Twitter - just by thinking about it.
Famed chemist, biotech pioneer and Harvard University professor George M. Whitesides will present "From Research to Commercial Reality, in the New World" at 5 p.m. on Monday, March 9, at the Fluno Center, 601 University Ave.
Warfarin, one of the world's most widely used drugs, is also one of the trickiest to prescribe. Half of those who take it are at risk of serious problems when given the standard starting dose.
Cellartis AB, a premier provider of human embryonic stem cell (hES) derived products and technologies, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin–Madison, announced today (Jan. 15) that they have signed a license for hES patents that enables Cellartis to commercialize undifferentiated hES cell products in the U.S.